(NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research

A Contract Award Notice
by NEWCASTLE UNIVERSITY

Source
OJEU
Type
Contract (Services)
Duration
not specified
Value
£30K
Sector
BUSINESS
Published
21 Oct 2022
Delivery
not specified
Deadline
n/a

Concepts

Location

Newcastle Upon Tyne

Geochart for 7 buyers and 1 suppliers

7 buyers

1 supplier

Description

Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US$92Bn in 2019 and is expected to reach US$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US$35.5Bn Million in 2018 and is projected to reach US$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively.

Total Quantity or Scope

Newcastle, Sunderland, Northumbria, Durham, Teesside universities together with the University of Bath on behalf of the SETsquared Partnership (the Enterprise collaboration of the Universities of Bath, Bristol, Exeter, Southampton and Surrey) and any other HE Institution that wishes to join this DPS, as detailed in the Office for Students Register, https://www.officeforstudents.org.uk/advice-and-guidance/the-register/the-ofs-re... will engage suitably qualified and experienced executives through the DPS as and when required over the DPS period. The specific requirements will be detailed in each individual further competition. The typical brief of an executive will be to: (a) Produce a viable business plan; (b) Obtain university approval for the venture; (c) Act for the company in the spin-out legal process and address all company formation matters; (d) Provide to the appropriate university all matters necessary for Research England and ESIF reporting requirements; (e) Secure (venture capital and/or other) funding in accordance with the business plan. This will be a cyclical process throughout the entire Research England, and potential ESIF project along with any additional funding streams.

Award Detail

1 Cambridge Drug Discovery (Cambridgeshire)
  • NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research
  • Reference: (nu/1433-37)
  • Num offers: 3
  • Value: £30,000
  • Contractor is an SME.

Award Criteria

• Ability to meet the required job description _
Quality: Ability to meet the Job Description 60.0
Equity share _
PRICE 40.0

CPV Codes

  • 79410000 - Business and management consultancy services

Indicators

  • Award on basis of price and quality.

Other Information

This an award from a DPS framework there was no pin and the contract notice was for the overall DPS itself. Overall Official Journal reference for the overall DPS is OJ S: 2022/S 186-528050

Reference

Domains